Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 8,722 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part A Clear all
Completed Phase 1 Interventional Results available

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

NCT04338685
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
Interventions
RO7119929, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

NCT06305715
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Radiation Therapy, Targeted TKI therapy
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

NCT00088543
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515
View directory record Official record
Conditions
Solid Tumor
Interventions
MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tepotinib Hepatic Impairment Trial

NCT03546608
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Tepotinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Not applicable Interventional

Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy

NCT02023008
View directory record Official record
Conditions
Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Fatigue, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
yoga therapy, internet-based intervention, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

NCT02062840
View directory record Official record
Conditions
Major Depression
Interventions
High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

NCT04057040
View directory record Official record
Conditions
Polycythemia Vera
Interventions
PTG-300, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • Greenbrae, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Results available

Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects

NCT01864291
View directory record Official record
Conditions
Bilateral Hearing Loss for Causes Other Than Tumors
Interventions
Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Months to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

NCT04345614
View directory record Official record
Conditions
Pneumonia
Interventions
Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2), Placebo (Part 2)
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improving Anticipatory and Compensatory Postural Responses to Avoid Falls After TBI

NCT05268484
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Perturbation-based Training with visual cues using Neurocom
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 20, 2026, 9:22 AM EDT
Active, not recruiting Not applicable Interventional

Matching Adults to Treatments for Chronic Pain (MATCH) Study

NCT05699252
View directory record Official record
Conditions
Chronic Pain
Interventions
Cognitive Behavioral Therapy (CBT), Hypnotic Cognitive Therapy (HYP-CT), Mindfulness-Based Cognitive Therapy (MBCT)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

NCT03211247
View directory record Official record
Conditions
Peanut Allergy
Interventions
Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 20, 2026, 9:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
48
States / cities
Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Phase 1Phase 2 Interventional

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

NCT01621243
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
nab-paclitaxel, gemcitabine, placebo, Necuparanib
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

NCT03512340
View directory record Official record
Conditions
Advanced Solid Cancers, Hematologic Cancers
Interventions
SRF231
Drug
Lead sponsor
Surface Oncology
Industry
Eligibility
18 Years to 99 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589
View directory record Official record
Conditions
B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Interventions
Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT06657768
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
LY4006895, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Los Alamitos, California • Lady Lake, Florida • Maitland, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Gluteal Squeeze for Left Colon Distension

NCT04827485
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Gluteal squeeze, No squeeze
Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

mTBI Identification and Monitoring Through Retinal Scanning

NCT06142435
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
Head and Intraocular Trauma Tool
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Financial Incentives to Improve Medication Adherence

NCT04191876
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions
Wellth - Financial Incentives
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Proprioception and Meditation

NCT03079817
View directory record Official record
Conditions
Parkinson Disease, Proprioceptive Disorders, Movement Disorders
Interventions
Yoga Meditation, Proprioceptive Drills
Other
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

NCT03541174
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

NCT05867420
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel
Biological · Drug
Lead sponsor
AskGene Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 20, 2026, 9:22 AM EDT